¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hyper-IgM Immunodeficiency Syndrome, Type 1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 5
¿µ¹® Horner syndrome ÇÑ±Û È£¸£³ÊÁõÈıº
¼³¸í   
  ±³°¨½Å°æ°æ·ÎÀÇ Àå¾Ö·Î »ý±â´Â º´ÀÌ´Ù. ±³°¨½Å°æÀº ÀÚÀ²½Å°æÀÇ Çϳª·Î ¿Â¸ö¿¡ ºÐÆ÷¸¦ ÇÑ´Ù. Æ¯È÷ ¾ó±¼ÂÊ¿¡´Â ´«²¨ÇÃÀ» ¿Ã¸®´Â ±ÙÀ°°ú ¶¡»ù¿¡ ºÐÆ÷Çϰí ÀÖ´Ù. À̿͠°°Àº ±³°¨½Å°æÀÇ ÀÛ¿ëÀ¸·Î ´«²¨Ç®À» Á¤»óÀûÀ¸·Î ¿Ã¸®°í ¾ó±¼¿¡ ¶¡ÀÌ ³ª¿À°Ô µÈ´Ù. ±× ¿Ü¿¡µµ ´«ÀÇ ºûÀÇ ¾çÀ» Á¶ÀýÇϴ ȫ並 ¼öÃà½Ã۴ ±ÙÀ°¿¡ ºÐÆ÷ÇØ¼­ ±× ÀÛ¿ëÀ¸·Î ´«ÀǠȫä°¡ ¼öÃàÇÏ¿© µ¿°øÀÌ Ä¿Áö°Ô µÈ´Ù. ±³°¨½Å°æÀº ±× ±â¿øÀÌ ´ë³ú¼Ó¿¡ Á¸ÀçÇϴ ½Ã»óÇϺζó´Â °÷À̰í À̰÷¿¡¼­ ½ÃÀÛÇÑ ±³°¨½Å°æÀº Ã´¼ö¸¦ Å¸°í ³»·Á¿Í¼­ ¸ñºÎÀ§¿¡¼­ Ã´¼ö¸¦ ºüÁ®³ª¿Í¼­ ±³°¨½Å°æÀ» Áٱ⸦ Çü¼ºÇÏ¿© ´Ù½Ã ³ú·Î °¡´Â Ç÷°üÀ» µû¶ó¼­ ¾ó±¼ÂÊÀ¸·Î °¡°ÔµÈ´Ù. ¸¸¾à ÀÌ ±³°¨½Å°æÀÇ ÁÖÇàºÎÀ§¿¡ º´º¯ÀÌ »ý±â¸é ±×ÂÊÀÇ ¾ó±¼¿¡ ±³°¨½Å°æÀÌ Â÷´ÜµÇ¹Ç·Î º´ÅÍÂÊÀÇ ´«ÀÇ ´«²¨Ç®ÃÄÁü, Ãൿ ±×¸®°í º´º¯Ãø ¾ó±¼ºÎÀÇ ¶¡ÀÌ ³ªÁö ¾Ê´Â °Í µîÀÇ Áõ»óÀ» ³ªÅ¸³ª°Ô µÈ´Ù. ÀÌ·± Çö»óÀ» È£¸£³ÊÁõÈıºÀ̶ó°í ÇÑ´Ù. À̰ÍÀº ¿©·¯ °¡Áö º´¿¡¼­ ³ªÅ¸³¯ ¼ö°¡ Àִµ¥ ³ú³ª Ã´¼öÀÇ ÁúȯÁß¿¡¼­ ÀÌ ±³°¨½Å°æ·Î¸¦ ¾Ð¹ÚÇϰųª Ä§¹üÇϴ º´¿¡¼­ »ý±æ ¼öµµ ÀÖÀ¸¸ç, ¶Ç´Â Æó¾ÏÀ̠ô¼ö¿¡¼­ ºüÁ®³ª¿Í ¸ñºÎºÐ¿¡¼­ ÀÌ·é ±³°¨½Å°æÀÇ Áٱ⸦ ´©¸¦ °æ¿ì¿¡µµ »ý±æ ¼öµµ ÀÖ´Ù.
¿µ¹® respiratory distress syndrome(RDS) ÇÑ±Û È£Èí°ï¶õÁõÈıº
¼³¸í   
  ÆóÆ÷¿Í Æó¸ð¼¼Ç÷°ü »çÀÌ¿¡ ºÎÁ¾À¸·Î ÀÎÇÑ È®»ê´É °¨¼Ò·Î È£Èí°ï¶õ°ú Ã»»öÁõÀ» º¸À̴ »óÅ·Π°¨¿°, ¼ö¼ú, ¿Ü»ó µî ¸ðµç Á¾·ùÀÇ ½ºÆ®·¹½º»óȲ¿¡¼­ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. Ä¡·á´Â ¼±Çà ¿äÀÎÀÇ ±³Á¤°ú ÀûÀýÇÑ Ç÷¾×³» »ê¼Ò³óµµ À¯ÁöÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Asherman¡¯s syndrome
    ¾Æ¼Å¸¸ÁõÈıº
  • auriculotemporal syndrome
    ±Ó¹ÙÄû°üÀÚÁõÈıº, À̰³ÃøµÎ½Å°æÁõÈıº
  • Ayerza syndrome
    ¾Æ¿¹¸£»çÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • acute respiratory distress syndrome
    ±Þ¼ºÈ£Èí°ï¶õÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å»ý½Ä±âÁõÈıº
  • adult respiratory distress syndrome
    ¼ºÀÎÈ£Èí°ï¶õÁõÈıº
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • afferent loop syndrome
    µéâÀÚÁõÈıº
  • Albright¡¯s syndrome
    ¿Ãºê¶óÀÌÆ®ÁõÈıº
  • Alport syndrome
    ¾ËÆ÷Æ®ÁõÈıº
  • alveolar hypoventilation syndrome
    ÆóÆ÷Àúȯ±âÁõÈıº
  • abstinence syndrome
    ±Ý´ÜÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • superior vena caval syndrome
    À§´ëÁ¤¸ÆÁõÈıº, »ó´ëÁ¤¸ÆÁõÈıº
  • systemic inflammatory response syndrome
    Àü½Å¿°Áõ¹ÝÀÀÁõÈıº
  • tarsal tunnel syndrome
    ¹ß¸ñ±¼ÁõÈıº, Á·±Ù°üÁõÈıº
  • testicular feminization syndrome
    °íȯ¿©¼ºÈ­ÁõÈıº
  • thoracic outlet syndrome
    °¡½¿¹®ÁõÈıº, Èä°ûÃⱸÁõÈıº
  • Turner's syndrome
    ÅͳÊÁõÈıº
  • withdrawal syndrome
    ±Ý´ÜÁõÈıº
  • Wolff-Parkinson White syndrome
    ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • WPW syndrome
    (¢¡Woff Parkinson White syndrome) ¿ùÇÁÆÄŲ½¼È­ÀÌÆ®ÁõÈıº
  • X syndrome
    ÁõÈıº¿¢½º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • type strain
    Ç¥ÁرÕÁÖ
  • type
    Çü, À¯Çü
  • test type
    ½Ã°¢Ç¥, ½ÃÇ¥
  • abstinence syndrome
    (¢¡withdrawal syndrome) ±Ý´ÜÁõÈıº
  • acquired immune deficiency syndrome
    ÈÄõ¸é¿ª°áÇÌÁõÈıº, ¿¡ÀÌÁî
  • acute brain syndrome
    ±Þ¼º³úÁõÈıº
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • adhesive syndrome
    À¯ÂøÁõÈıº
  • adrenogenital syndrome
    ºÎ½Å¼º±âÁõÈıº
  • adrenosympathetic syndrome
    ºÎ½Å±³°¨½Å°æÁõÈıº
  • advanced sleep phase syndrome
    ÀüÁø¼ö¸éÀ§»óÁõÈıº
  • aeroadaptation syndrome
    Ç×°ø¼øÀÀÁõÈıº
  • alveolar hypoventilation syndrome
    ÆóÆ÷Àúȯ±âÁõÈıº
  • alveolar-capillary block syndrome
    ÆóÆ÷¸ð¼¼Ç÷°üÂ÷´ÜÁõÈıº
  • amnestic syndrome
    ±â¾ï»ó½ÇÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • herpes simplex virus type 2
    Á¦2Çü ´Ü¼øÆ÷Áø¹ÙÀÌ·¯½º
  • htlv,type i
    type 1Çü
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type I
    Á¦1Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T¼¼Æ÷¹éÇ÷º´¹ÙÀÌ·¯½º
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • hyperlipoproteinemia type III
    °íÁö´Ü¹éÇ÷Áõ III
  • hyperlipoproteinemia type IV
    °í´Ü¹éÇ÷Áõ IV Çü
  • hyperlipoprotenemia type II
    °íÁö´Ü¹éÇ÷Áõ II Çü
  • hyperproteinemia type III
    ´Ü¹é°úÀ×Ç÷(Áõ) III Çü
  • hypersensitivity reactions,delayed-type
    Áö¿¬Çü(òÀæÅû¡)
  • hypersensitivity reactions,type i(anaphylactic)
    IÇü
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypersensitivity reactions,type iii(imune complex-mediated)
    IIIÇü
  • hypersensitivity reactions,type iv(cell-mediated)
    IVÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • body type
    üÇü(ô÷úþ).
  • bubble type vaporizer
    ±âÆ÷Çü ±âÈ­±â
  • calcified hypertrophic type
    ¼®È¸È­ºñ´ëÇü
  • catatonic type
    ±äÀåÇü
  • cellular type dermatofibroma
    ¼¼Æ÷Çü ÇǺμ¶À¯Á¾
  • chief cell type i glomus cell
    °ú¸³¼¼Æ÷
  • cryptogenic type
    ÀáÀçÇü(ËöËøÌ´).
  • cryptogenic type
    ÀáÀçÇü(íÖî¤úþ).
  • crystal type
    °áÁ¤Çü
  • culture, type
    Ç¥ÁرÕÁÖ, ±âÁØÁÖ
  • cyclicodevelopmental type
    ÁÖ±âÀû ¹ßÀ°Çü(ÊÙËÑËôÌ´).
  • cyclicopropagative type
    ÁÖ±âÀû Áõ½ÄÇü(ÊÙÌ¡ËàÌ´).
  • delayed type hypersensitivity
  • delayed-type hypersensitivity
    Áö¿¬Çü °ú¹Î¹ÝÀÀ
  • demand type pacemaker
    ¼ö¿äÇü½É¹ÚÁ¶À²±â.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PFKP phosphofructokinase, platelet type; 6-phosphofructo-2-kinase, platelet type
ABBQ Acquired Immunodeficiency Syndrome Beliefs and Behavior Questionnaire
AIDSLINE on-line information on acquired immunodeficiency syndrome [MEDLARS data base]
AIDSTRIALS clinical trials of acquired immunodeficiency syndrome drugs [MEDLARS data base]
ARV acquired immunodeficiency syndrome-related virus; anterior right ventricle; avian reovirus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CID Combined immunodeficiency
CVI Common variable immunodeficiency
FIV Feline Immunodeficiency Virus
HIV-1 Human Immunodeficiency Virus
HIV-1 Human Immunodeficiency Virus 1
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • schizoid type
    ºÐ¿­Çü
  • schizophrenia of childhood type
    ¾Æµ¿Çü Á¤½Å ºÐ¿­Áõ
    »çÃá±â¿¡ ¹ßº´ÇÏ´Â Á¤½Å ºÐ¿­ÁõÀ¸·Î¼­ ÀÚÆó¼º, ³»Ç⼺, ºñÁ¤ÇüÀû ÇൿÀ» Ư¡À¸·Î ÇÑ´Ù.
  • screen-type cassette
    ½ºÅ©¸°Çü Ä«¼¼Æ®
    ´ë°Ô ±Ý¼ÓÀ¸·Î ¸¸µé¾î Á³À¸¸ç, ³ëÃâ¸éÀº º£ÀÌŬ¶óÀÌÆ®, ¾Ë·ç¹Ì´½, ¸¶±×³×½·°ú °°Àº ³·Àº ¿øÀÚ ¹øÈ£ÀÇ ¹°Áú·Î µÇ¾î ÀÖ°í, Áõ°¨Áö¸¦ Æ÷ÇÔÇϰí À־ ±× »çÀÌ¿¡ X-¼± ³ëÃâÀ» À§ÇÑ "½ºÅ©¸°Çü" Çʸ§À» À§Ä¡½ÃŲ´Ù.
  • spaced type of deciduous dentition
    À¯±ØÇü À¯Ä¡¿­±Ã
  • spindle cell type
    ¹æÃß ¼¼Æ÷Çü
  • split electrode type probe
    ºÐÇÒ Àü±Ø ŽÃËÀÚ
  • sympathicotonic type
    ±³°¨½Å°æ ±äÀåÇü
  • target type
    ¸ñÇ¥¹° ÇüÅÂ
  • type A personality
    AÇü Àμº
  • type B personality
    BÇü Àμº
  • type cultural
    ´ëÇ¥ ±ÕÁ¾ ¹è¾ç, Ç¥ÁØ ¹è¾ç
  • type II
    2Çü
  • type III
    3Çü
  • type of eruption
    ¸ÍÃâÇü
  • type strain
    ´ëÇ¥ ±ÕÁ¾, Ç¥ÁØ ±ÕÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type V <disease> Glycogenosis due to muscle phosphorylase deficiency. Characterised by painful cramps following sustained exercise.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VI <disease> A hepatic glycogen storage disease in which there is an apparent deficiency of hepatic phosphorylase activity. However, studies have not been able to distinguish between phosphorylase deficiency and phosphorylase kinase deficiency in patients with hepatic glycogenosis.
(12 Dec 1998)
glycogen storage disease type VII <disease> An autosomal recessive muscle glycogen storage disease in which there is deficient expression of muscle phosphofructokinase activity, resulting in increased concentrations of glucose-6-phosphate and fructose-6-phosphate and low concentrations of fructose-1,6-diphosphate in muscle tissue.
Glycogen storage in muscle is increased, perhaps due to activation of glycogen synthase by accumulated glucose-6-phosphate. It has been proposed that shunting of glucose-6-phosphate and fructose-6-phosphate into the pentose phosphate pathway may result in increased synthesis of purines and pyrimidines, causing hyperuricaemia and gout.
Erythrocytes from patients may show decreased phosphofructokinase activity and 2,3-diphosphoglycerate deficiency. Exercise intolerance is present and severe congenital muscular dystrophy has been reported.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type VIII <disease> An x-linked recessive hepatic glycogen storage disease resulting from lack of expression of phosphorylase-b-kinase activity. Symptoms are relatively mild; hepatomegaly, increased liver glycogen, and decreased leukocyte phosphorylase are present. Liver shrinkage occurs in response to glucagon.
Inheritance: X-linked recessive
(12 Dec 1998)
V-type ATPase <enzyme> From eukaryotic endomembrane systems, including vacuoles, lysosomes, golgi apparatus, chromaffin granules and coated vesicles. One of three major classes of ion transport ATPase, characterised by a multi subunit structure and a lack of a phosphorylated intermediate.
Found in archaebacteria but not eubacteria, in the intracellular acidic vacuoles and in some proton pumping epithelia (e.g. Intercalated cells of kidney). A complex enzyme encoded by several genes, involved in ion translocation but does not act via phosphorylated enzyme intermediate
See: P-type ATPase.
Registry number: EC 3.6.1.-
Synonym: atpase, v-type, atpase, vacuolar, vacuolar atpase, v-atpase, vacuolar h+-atpase, vacuolar membrane h(+)-atpase, vha55 gene product, vma16 gene product
(26 Jun 1999)
Gm type <immunology> Genetically determined allotypic antigens found on IgG of some individuals.
(18 Nov 1997)
Golgi type II neuron <physiology> Nerve cells with short axons which ramify in the gray matter.
(05 Mar 2000)
Golgi type I neuron <physiology> Nerve cells whose long axons leave the gray matter of which they form a part.
(05 Mar 2000)
membrane-type 3 matrix metalloproteinase <enzyme> Sm3 is a soluble form of mt3-mmp, probably an alternatively sliced variant.
Registry number: EC 3.4.24.-
Synonym: mt3-mmp, sm3-mmp
(26 Jun 1999)
membrane-type 4 matrix metalloproteinase <enzyme> Cloned from breast carcinoma.
Registry number: EC 3.4.24.-
Synonym: mt4-mmp, mmp-17 gene product, mmp-17
(26 Jun 1999)
membrane-type matrix metalloproteinase <enzyme> Activates gelatinase a; isolated from a human placenta cdna gene library; contains a transmembrane domain; do not use for any other numbered matrix metalloproteinases; genbank d26512
Registry number: EC 3.4.24.-
Synonym: mt-mmp, mmp-x1 protein, matrix metalloproteinase, membrane-type, mmp14 gene product, mmp-14 gene product, mt1-mmp, matrix metalloproteinase 14, mt2-mmp, mmp15 gene product, mmp16 gene product
(26 Jun 1999)
retroviruses type b, mammalian A genus of the family retroviridae consisting of a few exogenous, vertically transmitted and endogenous viruses of mice. It is associated with mammary carcinoma and T-cell lymphoma.
(12 Dec 1998)
retroviruses type c, avian A genus of the family retroviridae with type c morphology, that causes malignant and other diseases in wild birds and domestic fowl.
(12 Dec 1998)
retroviruses type c, mammalian A genus of retroviridae comprising endogenous sequences in mammals, related reticuloendotheliosis viruses of birds, and a reptilian species. Many species contain oncogenes and cause leukaemias and sarcomas.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á